In Q4 2025, RA Capital Management held 68 positions worth $9.0B. They initiated 17 new positions and exited 78. Their largest holding was ASND ($2.2B). Portfolio value grew +17.9% versus the prior quarter.
Frequently asked questions
What stocks did RA Capital Management own in Q4 2025?
RA Capital Management held 68 biotech stocks in their 13F portfolio in Q4 2025. Their top positions include ASND, RYTM, RNA, PCVX, SION. The full holdings table is available on BiotechEdge with position sizes, quarter-over-quarter changes, and AI analysis.
How much was RA Capital Management's portfolio worth in Q4 2025?
RA Capital Management's tracked biotech portfolio was worth $9.0B across 68 positions, with total assets under management of approximately $10B. Portfolio values are based on 13F filings with the SEC.
What did RA Capital Management buy in Q4 2025?
RA Capital Management initiated 17 new positions in Q4 2025, including BCRX, OLMA, EVMN, SYRE, CAPR and 12 more. They also increased 17 existing positions.
What did RA Capital Management sell in Q4 2025?
RA Capital Management fully exited 78 positions in Q4 2025, including WHWK, RCKT, ENTX, CLDX, CMPS and 73 more. They also trimmed 8 existing positions.
Is RA Capital Management a biotech fund?
Crossover biotech fund that invests from late-stage private through public markets. Known for rigorous scientific analysis and the "biotech social contract" framework. Kolchinsky, a virologist by training, emphasizes understanding drug pricing dynamics and long-term value creation in biotech.
Want AI analysis, insider signals, and catalyst overlays for RA Capital Management?
View latest RA Capital Managementportfolio →